The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie

For Immediate Release

Chicago, IL – November 20, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Geron Corporation (GERN-Free Report), Gilead (GILD-Free Report), Regeneron (REGN-Free Report), Celldex Therapeutics, Inc. (CLDX-Free Report) and AbbVie (ABBV-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Biotech Stock Roundup

Geron Corporation (GERN-Free Report) was in the spotlight last week with the company striking a collaboration deal with Johnson & Johnson for its sole pipeline candidate, imetelstat. Meanwhile, companies like Gilead (GILD-Free Report) and Regeneron (REGN-Free Report) remained in the news thanks to regulatory updates.

Recap of the Week’s Most Important Stories

1. Geron, which had run into trouble earlier this year related to the development of its sole pipeline candidate, imetelstat, has struck a collaboration deal with Johnson & Johnson’s Janssen Biotech, Inc. Janssen gained exclusive global rights to develop and commercialize imetelstat for oncology, including hematologic malignancies, and other human therapeutics uses.

This agreement is a huge positive for Geron and comes shortly after the FDA lifted its full clinical hold on an investigational new drug (IND) application filed by the company for imetelstat. Under the Janssen collaboration, Geron could end up earning up to $935 million (including an upfront payment of $35 million) as well as royalties on sales.

Although Geron will be splitting development costs with Janssen and a major part of the payments from Janssen depends on the achievement of certain milestones, the agreement comes as a welcome respite for Geron shareholders – shares were up 19.5% immediately after the announcement and are up 37.2% so far (Read more: Geron Collaborates with J&J for Imetelstat).

2. Celldex Therapeutics, Inc.’s (CLDX-Free Report) shares shot up on encouraging interim data from a mid-stage study evaluating rindopepimut in patients with recurrent glioblastoma (Read more: Celldex Therapeutics Surges on Positive Rindopepimut Data).

3. Regeneron's blockbuster eye drug, Eylea, has gained approval for another indication, this time in Japan. Eylea, which was already approved in Japan for the treatment of patients with neovascular age-related macular degeneration, macular edema secondary to central retinal vein occlusion, and myopic choroidal neovascularization, can now be used for diabetic macular edema. Shares were up 3.4%.

4. Gilead is set to generate more sales from its hepatitis C virus (:HCV) franchise with its latest offering, Harvoni, now gaining EU approval as well. Harvoni was approved in the U.S. in October. Harvoni, a cocktail treatment, is a once-daily single tablet regimen comprising ledipasvir and Sovaldi. High cure rates and a convenient dosing regimen should drive uptake. However, AbbVie (ABBV-Free Report) could shortly enter the HCV market with its cocktail treatment which is currently under regulatory review.

5. CytRx Corporation has received a notice from the FDA informing the company that a partial clinical hold has been placed on studies being conducted with its experimental cancer treatment, aldoxorubicin. A partial clinical hold means that although currently enrolled patients will continue being treated, no new patients will be enrolled.

The FDA placed the partial clinical hold due to the reported death of an advanced-stage cancer patient who had received the experimental treatment under the company's compassionate use program. CytRx is working on getting the partial clinical hold lifted and does not expect study timelines to be materially impacted by this development.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on GERN - FREE
Get the full Report on GILD - FREE
Get the full Report on REGN - FREE
Get the full Report on CLDX - FREE
Get the full Report on ABBV - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on GERN

Read the analyst report on GILD

Read the analyst report on REGN

Read the analyst report on CLDX

Read the analyst report on ABBV


Zacks Investment Research